Trial NCT07226843
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Phase
- Phase 1
- Sponsor
- Eli Lilly and Company
- Conditions
- Lymphoma, Non-Hodgkin's; Lymphoma, Diffuse Large B-Cell; Follicular Lymphoma
- Ages
- 18+ years
Eligibility criteria
Highlighted: restrictions our model extracted, each a verbatim quote (pink = excludes outright, blue = only under conditions).
Inclusion Criteria:
* Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:
* Diffuse large B-cell lymphoma - not otherwise specified
* High-grade B-cell lymphoma
* Diffuse large B-cell lymphoma - transformed from indolent lymphomas
* Follicular large B-cell lymphoma
* Follicular lymphoma
* Other non-Hodgkin lymphoma
* Has measurable disease
* Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy
Exclusion Criteria:
* Has an active second cancerPrior malignancy
* Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.Brain metastases
* Has known Cytomegalovirus infection. Participants with negative status are eligible
* Has known hepatitis B or C infection or uncontrolled HIVHIV
* Has known significant heart diseaseCardiac
Restrictions found (4)
- Brain metastasesConditionalexclusionShow in the text
- CardiacConditionalexclusionShow in the text
- HIVConditionalexclusionShow in the text
- Prior malignancyConditionalexclusionShow in the text
Recruiting in Massachusetts
- Massachusetts General Hospital · Boston, Suffolk County
- Dana-Farber Cancer Institute · Boston, Suffolk County